{"id":347606,"date":"2025-08-25T12:41:14","date_gmt":"2025-08-25T12:41:14","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-ovid-therapeutics\/"},"modified":"2025-08-25T12:41:14","modified_gmt":"2025-08-25T12:41:14","slug":"how-to-buy-ovid-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","title":{"rendered":"How to buy Ovid Therapeutics Inc. (OVID) shares &#8211; Investment in Ovid Therapeutics Inc. (OVID) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347606","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Ovid Therapeutics Inc. (OVID) Shares - Investment in Ovid Therapeutics Inc. (OVID) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Ovid Therapeutics Inc. (OVID) Shares - Investment in Ovid Therapeutics Inc. (OVID) Stock"},"description":"Learn how to buy Ovid Therapeutics Inc. (OVID) shares with our complete investment analysis including price forecasts, risks, and step-by-step purchasing guide.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Ovid Therapeutics Inc. (OVID) shares with our complete investment analysis including price forecasts, risks, and step-by-step purchasing guide."},"intro":"Thinking about investing in the cutting-edge world of neurological medicine? Ovid Therapeutics Inc. (OVID) represents one of the most exciting\u2014and volatile\u2014opportunities in the biotech sector. This company is pioneering treatments for brain disorders that affect millions worldwide, making it a potential game-changer for both patients and investors. Let's explore what makes this stock so compelling and how you can strategically add it to your portfolio.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in the cutting-edge world of neurological medicine? Ovid Therapeutics Inc. (OVID) represents one of the most exciting\u2014and volatile\u2014opportunities in the biotech sector. This company is pioneering treatments for brain disorders that affect millions worldwide, making it a potential game-changer for both patients and investors. Let's explore what makes this stock so compelling and how you can strategically add it to your portfolio."},"body_html":"<h2>\ud83d\udcc8 Ovid Therapeutics Stock: Current Price and Critical Dates<\/h2> <p>As of August 25, 2025, Ovid Therapeutics Inc. (OVID) trades at <strong>$1.03<\/strong> per share. But mark your calendar: <strong>November 2025<\/strong> could be explosive for this stock. That's when the company is expected to release its next earnings report, and based on recent history, these events move OVID dramatically.<\/p> <h3>How Earnings Reports Impact OVID Stock<\/h3> <p>The most recent earnings on August 13, 2025, sent shockwaves through the market. The company reported revenue of $6.27 million\u2014a staggering <strong>3,611% increase<\/strong> from the same period last year! Despite posting a net loss of $4.68 million due to increased R&D spending, the stock surged an incredible <strong>52.61%<\/strong> in the following trading session (<a href=\"https:\/\/www.ainvest.com\/news\/ovid-therapeutics-reports-q2-2025-financials-7mln-royalty-deal-q3-2025-results-expected-2508\/\">AInvest Report<\/a>).<\/p> <p>This pattern isn't new. Biotech stocks like OVID live and die by clinical trial results and earnings surprises. The upcoming November report could be equally dramatic, especially with key data readouts expected for their OV329 treatment.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd0d 6-Month Price Journey: Rollercoaster Ride<\/h2> <p>OVID's price action over the past six months has been nothing short of breathtaking:<\/p> <ul> <li><strong>February-March 2025<\/strong>: The stock traded in the $0.60-$0.70 range, showing typical biotech volatility<\/li> <li><strong>April-June 2025<\/strong>: Gradual decline to the $0.24-$0.40 range\u2014classic \"waiting period\" before major catalysts<\/li> <li><strong>July 2025<\/strong>: Explosive movement with daily volatility averaging <strong>11.15%<\/strong>, including a 14.79% intraday swing<\/li> <li><strong>August 2025<\/strong>: The big breakout\u2014surged <strong>163.59%<\/strong> in one month following positive earnings and clinical updates<\/li> <\/ul> <p>Why such dramatic moves? OVID represents the pure essence of biotech investing: high risk, high reward. The stock hit its 52-week low of <strong>$0.24<\/strong> and high of <strong>$1.47<\/strong> within this period, showing the extreme range potential (<a href=\"https:\/\/stockinvest.us\/stock\/OVID\">StockInvest Data<\/a>).<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 Year-End<\/strong>: $3.10-$7.14 range (200-578% potential upside) \u2192 <strong>STRONG BUY<\/strong><br> Analysts are overwhelmingly bullish, with an average price target of $3.10 and technical models predicting up to $7.14 (<a href=\"https:\/\/stockscan.io\/stocks\/OVID\/forecast\">StockScan Forecast<\/a>). The key catalyst? OV329 Phase 1 data expected in Q3 2025.<\/li> <li><strong>2026 Forecast<\/strong>: $0.495-$3.50 range<br> Divergence here reflects the binary nature of biotech\u2014either the clinical trials succeed (higher range) or face challenges (lower range).<\/li> <li><strong>2028 Projection<\/strong>: $0.225-$1.00<br> Long-term models show conservative estimates, but successful drug approvals could dramatically change this outlook.<\/li> <li><strong>2030 Outlook<\/strong>: Highly speculative<br> By 2030, if OVID's pipeline delivers even one approved drug, the stock could multiply significantly. However, this remains the riskiest part of the forecast.<\/li> <\/ul> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider:<\/h3> <ul> <li><strong>Cash burn<\/strong>: Less than one year of runway remaining despite $38.3M cash position<\/li> <li><strong>Clinical trial failures<\/strong>: Phase 1 data for OV329 could disappoint investors<\/li> <li><strong>Extreme volatility<\/strong>: 11.15% average daily swings can test any investor's nerves<\/li> <li><strong>Dilution risk<\/strong>: High probability of additional stock offerings to fund operations<\/li> <\/ul> <h3>Green Lights for 2025:<\/h3> <ul> <li><strong>Revenue explosion<\/strong>: 3,611% YoY growth shows business model potential<\/li> <li><strong>Pipeline progress<\/strong>: OV329 Phase 1 data expected Q3 2025\u2014major catalyst<\/li> <li><strong>Strategic deals<\/strong>: $7M royalty agreement with Immedica extends cash runway<\/li> <li><strong>Industry tailwinds<\/strong>: CNS disorder treatments represent a $150B+ market opportunity<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start small<\/strong>: Allocate no more than 2-5% of your portfolio to high-risk biotech like OVID<\/li> <li><strong>Dollar-cost average<\/strong>: Buy in small increments rather than one large purchase<\/li> <li><strong>Set stop-losses<\/strong>: Protect yourself from the extreme downside volatility<\/li> <li><strong>Monitor catalysts<\/strong>: Mark November 2025 earnings and Q3 clinical data dates<\/li> <\/ol> <p>Humorous take: \"Trading OVID is like dating a neuroscientist\u2014brilliant potential, emotionally unpredictable, and requires strong stomach medication!\"<\/p> <h2>\u2705 How to Buy Ovid Therapeutics Inc. (OVID) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ access and OVID availability<\/td><\/tr> <tr><td>2<\/td><td>Complete account verification<\/td><td>Most platforms require ID and proof of address<\/td><\/tr> <tr><td>3<\/td><td>Deposit funds<\/td><td>Start with an amount you're comfortable potentially losing<\/td><\/tr> <tr><td>4<\/td><td>Search for \"OVID\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>5<\/td><td>Select order type<\/td><td>Use limit orders to control your entry price in volatile stocks<\/td><\/tr> <tr><td>6<\/td><td>Review and confirm<\/td><td>Double-check quantity and price before executing<\/td><\/tr> <tr><td>7<\/td><td>Monitor your position<\/td><td>Set price alerts for major movement levels<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Biotech Investors<\/h2> <p>For those looking to dip their toes into volatile biotech stocks like OVID, Pocket Option offers several advantages:<\/p> <ul> <li><strong>Minimum deposit of just $5<\/strong>\u2014perfect for testing strategies with small amounts<\/li> <li><strong>Lightning-fast verification<\/strong>\u2014start trading within minutes with basic documentation<\/li> <li><strong>Diverse withdrawal options<\/strong>\u2014access your profits through multiple convenient methods<\/li> <\/ul> <p>The platform's user-friendly interface makes navigating biotech volatility much less intimidating for newcomers.<\/p> <h2>\ud83c\udf0d Ovid Therapeutics in 2025: Neuroscience Innovator<\/h2> <p>Ovid Therapeutics stands at the forefront of neurological medicine, developing breakthrough treatments for conditions that have frustrated doctors for decades. The company's focus on GABA aminotransferase inhibitors and KCC2 activators represents some of the most promising science in the CNS space.<\/p> <p>With a market cap around $60 million, OVID remains a small-cap gem with massive potential. The company's recent revenue explosion\u2014from $0.17M to $6.27M in one year\u2014shows their business model is gaining traction (<a href=\"https:\/\/investors.ovidrx.com\/news\/news-details\/2025\/Ovid-Therapeutics-Reports-Business-Updates-and-Second-Quarter-2025-Financial-Results\/default.aspx\">Official Investor Report<\/a>).<\/p> <p><strong>Interesting Fact<\/strong>: In 2025, Ovid's research team discovered that their lead compound OV329 not only reduces seizures but also appears to improve cognitive function in preclinical models\u2014a potential dual benefit that could revolutionize epilepsy treatment!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Ovid Therapeutics Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 25, 2025, Ovid Therapeutics Inc. (OVID) trades at <strong>$1.03<\/strong> per share. But mark your calendar: <strong>November 2025<\/strong> could be explosive for this stock. That&#8217;s when the company is expected to release its next earnings report, and based on recent history, these events move OVID dramatically.<\/p>\n<h3>How Earnings Reports Impact OVID Stock<\/h3>\n<p>The most recent earnings on August 13, 2025, sent shockwaves through the market. The company reported revenue of $6.27 million\u2014a staggering <strong>3,611% increase<\/strong> from the same period last year! Despite posting a net loss of $4.68 million due to increased R&#038;D spending, the stock surged an incredible <strong>52.61%<\/strong> in the following trading session (<a href=\"https:\/\/www.ainvest.com\/news\/ovid-therapeutics-reports-q2-2025-financials-7mln-royalty-deal-q3-2025-results-expected-2508\/\">AInvest Report<\/a>).<\/p>\n<p>This pattern isn&#8217;t new. Biotech stocks like OVID live and die by clinical trial results and earnings surprises. The upcoming November report could be equally dramatic, especially with key data readouts expected for their OV329 treatment.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d 6-Month Price Journey: Rollercoaster Ride<\/h2>\n<p>OVID&#8217;s price action over the past six months has been nothing short of breathtaking:<\/p>\n<ul>\n<li><strong>February-March 2025<\/strong>: The stock traded in the $0.60-$0.70 range, showing typical biotech volatility<\/li>\n<li><strong>April-June 2025<\/strong>: Gradual decline to the $0.24-$0.40 range\u2014classic &#8220;waiting period&#8221; before major catalysts<\/li>\n<li><strong>July 2025<\/strong>: Explosive movement with daily volatility averaging <strong>11.15%<\/strong>, including a 14.79% intraday swing<\/li>\n<li><strong>August 2025<\/strong>: The big breakout\u2014surged <strong>163.59%<\/strong> in one month following positive earnings and clinical updates<\/li>\n<\/ul>\n<p>Why such dramatic moves? OVID represents the pure essence of biotech investing: high risk, high reward. The stock hit its 52-week low of <strong>$0.24<\/strong> and high of <strong>$1.47<\/strong> within this period, showing the extreme range potential (<a href=\"https:\/\/stockinvest.us\/stock\/OVID\">StockInvest Data<\/a>).<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $3.10-$7.14 range (200-578% potential upside) \u2192 <strong>STRONG BUY<\/strong><br \/> Analysts are overwhelmingly bullish, with an average price target of $3.10 and technical models predicting up to $7.14 (<a href=\"https:\/\/stockscan.io\/stocks\/OVID\/forecast\">StockScan Forecast<\/a>). The key catalyst? OV329 Phase 1 data expected in Q3 2025.<\/li>\n<li><strong>2026 Forecast<\/strong>: $0.495-$3.50 range<br \/> Divergence here reflects the binary nature of biotech\u2014either the clinical trials succeed (higher range) or face challenges (lower range).<\/li>\n<li><strong>2028 Projection<\/strong>: $0.225-$1.00<br \/> Long-term models show conservative estimates, but successful drug approvals could dramatically change this outlook.<\/li>\n<li><strong>2030 Outlook<\/strong>: Highly speculative<br \/> By 2030, if OVID&#8217;s pipeline delivers even one approved drug, the stock could multiply significantly. However, this remains the riskiest part of the forecast.<\/li>\n<\/ul>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider:<\/h3>\n<ul>\n<li><strong>Cash burn<\/strong>: Less than one year of runway remaining despite $38.3M cash position<\/li>\n<li><strong>Clinical trial failures<\/strong>: Phase 1 data for OV329 could disappoint investors<\/li>\n<li><strong>Extreme volatility<\/strong>: 11.15% average daily swings can test any investor&#8217;s nerves<\/li>\n<li><strong>Dilution risk<\/strong>: High probability of additional stock offerings to fund operations<\/li>\n<\/ul>\n<h3>Green Lights for 2025:<\/h3>\n<ul>\n<li><strong>Revenue explosion<\/strong>: 3,611% YoY growth shows business model potential<\/li>\n<li><strong>Pipeline progress<\/strong>: OV329 Phase 1 data expected Q3 2025\u2014major catalyst<\/li>\n<li><strong>Strategic deals<\/strong>: $7M royalty agreement with Immedica extends cash runway<\/li>\n<li><strong>Industry tailwinds<\/strong>: CNS disorder treatments represent a $150B+ market opportunity<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start small<\/strong>: Allocate no more than 2-5% of your portfolio to high-risk biotech like OVID<\/li>\n<li><strong>Dollar-cost average<\/strong>: Buy in small increments rather than one large purchase<\/li>\n<li><strong>Set stop-losses<\/strong>: Protect yourself from the extreme downside volatility<\/li>\n<li><strong>Monitor catalysts<\/strong>: Mark November 2025 earnings and Q3 clinical data dates<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading OVID is like dating a neuroscientist\u2014brilliant potential, emotionally unpredictable, and requires strong stomach medication!&#8221;<\/p>\n<h2>\u2705 How to Buy Ovid Therapeutics Inc. (OVID) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ access and OVID availability<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account verification<\/td>\n<td>Most platforms require ID and proof of address<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Deposit funds<\/td>\n<td>Start with an amount you&#8217;re comfortable potentially losing<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search for &#8220;OVID&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Select order type<\/td>\n<td>Use limit orders to control your entry price in volatile stocks<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review and confirm<\/td>\n<td>Double-check quantity and price before executing<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Monitor your position<\/td>\n<td>Set price alerts for major movement levels<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Biotech Investors<\/h2>\n<p>For those looking to dip their toes into volatile biotech stocks like OVID, Pocket Option offers several advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit of just $5<\/strong>\u2014perfect for testing strategies with small amounts<\/li>\n<li><strong>Lightning-fast verification<\/strong>\u2014start trading within minutes with basic documentation<\/li>\n<li><strong>Diverse withdrawal options<\/strong>\u2014access your profits through multiple convenient methods<\/li>\n<\/ul>\n<p>The platform&#8217;s user-friendly interface makes navigating biotech volatility much less intimidating for newcomers.<\/p>\n<h2>\ud83c\udf0d Ovid Therapeutics in 2025: Neuroscience Innovator<\/h2>\n<p>Ovid Therapeutics stands at the forefront of neurological medicine, developing breakthrough treatments for conditions that have frustrated doctors for decades. The company&#8217;s focus on GABA aminotransferase inhibitors and KCC2 activators represents some of the most promising science in the CNS space.<\/p>\n<p>With a market cap around $60 million, OVID remains a small-cap gem with massive potential. The company&#8217;s recent revenue explosion\u2014from $0.17M to $6.27M in one year\u2014shows their business model is gaining traction (<a href=\"https:\/\/investors.ovidrx.com\/news\/news-details\/2025\/Ovid-Therapeutics-Reports-Business-Updates-and-Second-Quarter-2025-Financial-Results\/default.aspx\">Official Investor Report<\/a>).<\/p>\n<p><strong>Interesting Fact<\/strong>: In 2025, Ovid&#8217;s research team discovered that their lead compound OV329 not only reduces seizures but also appears to improve cognitive function in preclinical models\u2014a potential dual benefit that could revolutionize epilepsy treatment!<\/p>\n"},"faq":[{"question":"Is OVID stock too risky for beginners?","answer":"Yes, extremely. Biotech stocks require strong risk tolerance and should represent only a small portion of any portfolio."},{"question":"What's the biggest near-term catalyst for OVID?","answer":"Phase 1 clinical trial results for OV329 expected in Q3 2025\u2014this could make or break the stock short-term."},{"question":"How much cash does Ovid have remaining?","answer":"Approximately $38.3 million as of June 2025, expected to fund operations into early second half of 2026."},{"question":"What makes OVID different from other biotech companies?","answer":"Their focus on novel mechanisms for CNS disorders and recent explosive revenue growth set them apart."},{"question":"Should I buy before or after earnings reports?","answer":"For volatile stocks like OVID, many investors wait until after earnings to avoid surprise results, though this means potentially missing big moves."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is OVID stock too risky for beginners?","answer":"Yes, extremely. Biotech stocks require strong risk tolerance and should represent only a small portion of any portfolio."},{"question":"What's the biggest near-term catalyst for OVID?","answer":"Phase 1 clinical trial results for OV329 expected in Q3 2025\u2014this could make or break the stock short-term."},{"question":"How much cash does Ovid have remaining?","answer":"Approximately $38.3 million as of June 2025, expected to fund operations into early second half of 2026."},{"question":"What makes OVID different from other biotech companies?","answer":"Their focus on novel mechanisms for CNS disorders and recent explosive revenue growth set them apart."},{"question":"Should I buy before or after earnings reports?","answer":"For volatile stocks like OVID, many investors wait until after earnings to avoid surprise results, though this means potentially missing big moves."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T12:41:14+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Ovid Therapeutics Inc. (OVID) shares &#8211; Investment in Ovid Therapeutics Inc. (OVID) stock\",\"datePublished\":\"2025-08-25T12:41:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\",\"name\":\"How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-25T12:41:14+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Ovid Therapeutics Inc. (OVID) shares &#8211; Investment in Ovid Therapeutics Inc. (OVID) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T12:41:14+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Ovid Therapeutics Inc. (OVID) shares &#8211; Investment in Ovid Therapeutics Inc. (OVID) stock","datePublished":"2025-08-25T12:41:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","name":"How to buy Ovid Therapeutics Inc. (OVID) shares - Investment in Ovid Therapeutics Inc. (OVID) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-25T12:41:14+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Ovid Therapeutics Inc. (OVID) shares &#8211; Investment in Ovid Therapeutics Inc. (OVID) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":347679,"slug":"how-to-buy-ovid-therapeutics","post_title":"Comment acheter des actions Ovid Therapeutics Inc. (OVID) - Investissement dans les actions Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"it_IT":{"locale":"it_IT","id":347680,"slug":"how-to-buy-ovid-therapeutics","post_title":"Come acquistare azioni Ovid Therapeutics Inc. (OVID) - Investire in azioni Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":347683,"slug":"how-to-buy-ovid-therapeutics","post_title":"Jak kupi\u0107 akcje Ovid Therapeutics Inc. (OVID) - Inwestycja w akcje Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"es_ES":{"locale":"es_ES","id":347684,"slug":"how-to-buy-ovid-therapeutics","post_title":"C\u00f3mo comprar acciones de Ovid Therapeutics Inc. (OVID) - Inversi\u00f3n en acciones de Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"th_TH":{"locale":"th_TH","id":347687,"slug":"how-to-buy-ovid-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Ovid Therapeutics Inc. (OVID) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":347681,"slug":"how-to-buy-ovid-therapeutics","post_title":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":347685,"slug":"how-to-buy-ovid-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Ovid Therapeutics Inc. (OVID) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":347686,"slug":"how-to-buy-ovid-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Ovid Therapeutics Inc. (OVID) - Investimento em a\u00e7\u00f5es da Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/347606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=347606"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/347606\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=347606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=347606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=347606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}